Lung Cancer Clinical Trials in San Diego

Showing 181-200 of 520 trials

Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

NCT05783622

This study is a first-in-human (FIH), Phase 1/1b, open-label, multicenter dose escalation and dose expansion study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of JANX008 in adult subjects with advanced or metastatic carcinoma expressing EGFR.

Non-Small Cell Lung CancerRenal Cell CarcinomaSquamous Cell Carcinoma of the Head and Neck+4 more

Janux Therapeutics130 participantsStarted Apr 2023

Duarte, California, United States • Sacramento, California, United States • San Diego, California, United States +15 more locations

TERMINATEDPhase 211 miles

Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC

NCT04926831

This study was planned to determine if neoadjuvant capmatinib could improve the major pathological response (MPR) in patients with Stage IB-IIIA, N2 and selected IIIB (T3N2 or T4N2) lung cancers with Mesenchymal Epithelial Transition (MET) exon 14 mutations and/or high MET amplification beyond those achieved with surgery, chemotherapy, and radiation. Treatment was to be continued with capmatinib in the adjuvant setting to evaluate the potential clinical benefit of extended therapy. The purpose of this study is to determine if neoadjuvant capmatinib can improve outcomes in participants with stages I-IIIA non-small cell lung cancer with MET exon 14 mutations and/or high MET amplification beyond those achieved with surgery, chemotherapy, and radiation.

Non-small Cell Lung Cancer

Novartis Pharmaceuticals4 participantsStarted Aug 2022

La Jolla, California, United States • La Jolla, California, United States • Sacramento, California, United States +3 more locations

Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC

Lung Cancer Trials in Other Cities

Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer

Study With Various Immunotherapy Treatments in Participants With Lung Cancer

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)

A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation

A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations

Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors

To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation

A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer

A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies

Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas

Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC Subjects

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

Other Conditions in San Diego